Postmenopozal dönemde östradiol-valerat + siproteron asetat ve tibolon' un lipid profiline etkilerinin karşılaştırılması
Küçük Resim Yok
Tarih
1998
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada; postmenopozal hormon replasman tedavisinde (HRT) kullanılan Östradiol Valerat+Siproteron Asetat (EV-CPA) ve Tibolon'un lipid profiline etkileri karşılaştırılmıştır. Kardiyovasküler hastalık (KVH) için risk faktörü olarak, diyabetes mellitus, hipertansiyon, sigara öyküsü olmayan, en az bir yıldır amenorede, hormon profili menopoz ile uyumlu 80 hasta seçilmiştir. Hastalar daha önce HRT kullanmamış ve HRT için risk faktörleri saptanmamıştır. Tedavi öncesi her hastadan lipid profili bakılmış ve 80 hasta içinden 30 hastaya bir yıl boyunca EV-CPA (grup I), 50 hastaya tibolon (grup II) tedavisi verilmiştir. Bir yıl sonra lipid profili tekrarlanmıştır. Grup l'de tedavi sonrası HDL-K'de istatistiksel olarak anlamsız bir yük-selme (p>0.05), LDL-K'de anlamlı bir düşme (p<0.05), Total-Kde ise anlamlı bir düşme (p<0.05) saptanmıştır. Tibolon kulla-nan grupda; tedavi sonrası HDL-K de istatistiksel olarak anlamlı bir düşme (p<0.05), LDL-K'de anlamsız bir düşme (p>0.05), Total-K'de ise anlamlı bir düşme (p<0.05) tespit edilmiştir, iki grup tedavi sonrası karşılaştırıldığında HDL-K ve LDL-K de istatisitiksel olarak anlamlı bir fark saptanırken Total-K'de bir fark saptanmamıştır (p>0.05). Bir yıllık tedavi sonucunda; tibolonun HDL-K'da oluşturduğu belirgin azalma ile lipid profiline olumsuz etkisi, E2\/-CPA'nın ise olumlu etkisi saptanmıştır.
The effects of estradiol valerate+cyproterone acetate and tibolon, on the lipid profile have been compared. These drugs have been used for hormone replacement therapy (HRT) in 80 postmenopausal women whose hormone profiles were in accordance with menopausal values and had a history of at least one year of amenorrhoea without any risk factors for cardiovascular disease such as diabetes, hypertension and smoking. The patients had not used HRT previously and had no risk factors for HRT. Before the commencement of therapy, lipid profiles have been determined for each patient. Thirty patients received EV-CPA (group I) and 50 patients received tibolon (group II) for one year. At the and of the year, the lipid profiles have been repeated. After the therapy, in group I, statistically insignificant increase in HDL cholesterol (p>0.05), statistically significant decrease in LDL cholesterol (p<0.05) and statistically significant decrease in total cholesterol (p<0.05) have been found. In the tibolon group (group II), statistically significant decrease in HDL cholesterol (p<0.05), statistically insignificant decrease in LDL cholesterol (p>0.05), and statistically significant decrease in total cholesterol have been determined. When the two groups have been compared after one year therapy there was a statistically significant difference in HDL cholesterol and LDL cholesterol, no difference in total cholesterol (p>0.05) was found. After one year of therapy, tibolon has been shown to decrease HDL cholesterol whereas EV-CPA has increased HDL cholesterol.
The effects of estradiol valerate+cyproterone acetate and tibolon, on the lipid profile have been compared. These drugs have been used for hormone replacement therapy (HRT) in 80 postmenopausal women whose hormone profiles were in accordance with menopausal values and had a history of at least one year of amenorrhoea without any risk factors for cardiovascular disease such as diabetes, hypertension and smoking. The patients had not used HRT previously and had no risk factors for HRT. Before the commencement of therapy, lipid profiles have been determined for each patient. Thirty patients received EV-CPA (group I) and 50 patients received tibolon (group II) for one year. At the and of the year, the lipid profiles have been repeated. After the therapy, in group I, statistically insignificant increase in HDL cholesterol (p>0.05), statistically significant decrease in LDL cholesterol (p<0.05) and statistically significant decrease in total cholesterol (p<0.05) have been found. In the tibolon group (group II), statistically significant decrease in HDL cholesterol (p<0.05), statistically insignificant decrease in LDL cholesterol (p>0.05), and statistically significant decrease in total cholesterol have been determined. When the two groups have been compared after one year therapy there was a statistically significant difference in HDL cholesterol and LDL cholesterol, no difference in total cholesterol (p>0.05) was found. After one year of therapy, tibolon has been shown to decrease HDL cholesterol whereas EV-CPA has increased HDL cholesterol.
Açıklama
Anahtar Kelimeler
Cerrahi
Kaynak
Ege Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
37
Sayı
3-4
